Harvard Bioscience (HBIO) Raw Materials (2011 - 2026)

Harvard Bioscience (HBIO) has 16 years of Raw Materials data on file, last reported at $13.3 million in Q1 2026.

• On a quarterly basis, Raw Materials fell 9.09% year-over-year to $13.3 million in Q1 2026; TTM through Mar 2026 was $13.3 million, a 9.09% decrease from a year earlier, with the FY2025 full-year figure at $12.2 million, down 20.28% from the prior year.
• Raw Materials for Q1 2026 stood at $13.3 million, up from $12.2 million in the prior quarter.
• Over the last five years, Raw Materials for HBIO reached as high as $19.2 million in Q2 2022 and fell as low as $12.2 million in Q4 2025.
• Historically, Raw Materials has averaged $15.9 million across 5 years, with a median of $15.4 million in 2023.
• Across the five-year window, Raw Materials soared 31.79% in 2022 and dropped 24.1% in 2025, its largest moves.
• Year by year, Raw Materials stood at $17.4 million in 2022, then slipped by 11.65% to $15.4 million in 2023, then fell by 0.9% to $15.3 million in 2024, then slipped by 20.28% to $12.2 million in 2025, then gained by 9.58% to $13.3 million in 2026.
• Per Business Quant data, the three most recent Raw Materials figures were $13.3 million in Q1 2026, $12.2 million in Q4 2025, and $13.5 million in Q3 2025.